-
Mashup Score: 0
Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Martin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Martin Dreyling, MD, discusses the next steps for research with #ibrutinib in the #MCL space following the presentation of data from the phase 3 TRIANGLE study. #lymsm https://t.co/JnIZsiDrsT
-
-
Mashup Score: 1Zanubrutinib Among Patients With B-Cell Malignancies Intolerant of Other BTK Inhibitors - 1 year(s) ago
Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mazyar Shadman, MD, stated, “#zanubrutinib, a safe and viable treatment for patients with B-cell malignancies, might fill that unmet need for those who exhibit intolerance to #ibrutinib or #acalabrutinib.” Read more here: https://t.co/kugGL82drX @mshadman @fredhutch https://t.co/C9lvjWQoPi
-
-
Mashup Score: 0Adding Ibrutinib to Induction or Maintenance With or Without AutoHSCT Shows Strong Efficacy, Acceptable Toxicity in MCL - 1 year(s) ago
Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of #ibrutinib to induction or maintenance treatment with or without #autoHSCT in younger patients with #MCL showed promising results. Follow along as Martin Dreyling, MD, shares his insights! https://t.co/zaIezWc7mF https://t.co/KtHjGgqdC9
-
-
Mashup Score: 0
Results of a phase 2 trial indicate that BTK inhibitor ibrutinib plus lenalidomide and rituximab led to antitumor activity with durable responses among patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Recent #Hematology news findings indicate that #ibrutinib, a #BTK inhibitor, plus #lenalidomide and #rituximab demonstrated antitumor activity with durable responses among patients with R/R #DLBCL. Read more here: https://t.co/6ZQEhsYkNg @uthsc https://t.co/xy2MAHC1m1
-
-
Mashup Score: 0
Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscape Cash runway extended to 2025, enabling initial clinical data readouts for both ONCT-808, ROR1-tageting CAR T for patients with aggre ssive lymphomas, and ONCT-534,
Source: Oncternal Therapeutics Inc.Categories: Hem/Oncs, Latest HeadlinesTweet-
Zilovertamab Phase 3 Study ZILO-301 a casualty of recent #ibrutinib #MCL #FDA announcement https://t.co/qGhGxsdNkT
-
-
Mashup Score: 0Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 4/12/2023 5:26:00 PM Last Updated: 4/14/2023 12:48:46 PM AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States https://t.co/qs5wsbMQwC #lymsm #lymphoma #ibrutinib
-
-
Mashup Score: 0
Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Ibrutinib has been voluntarily withdrawn from the US market as a treatment option for patients with #MCL and #MZL. #lymsm https://t.co/rb6CdTsO6S
-
-
Mashup Score: 0Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn - 1 year(s) ago
Janssen and Pharmacyclics intends to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.The withdraw applies only to ibrutinib indications for patients with mantle cell lymphoma who received at least one previous therapy and for patients with marginal zone lymphoma who need systemic treatment after at least one previous
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WITHDRAWN: Ibrutinib indications for mantle cell, marginal zone lymphoma. https://t.co/SudsyS8wVk #Ibrutinib @JanssenUS @Pharmacyclics #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 2Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications | AbbVie News Center - 1 year(s) ago
NORTH CHICAGO, Ill., April 6, 2023 – AbbVie (NYSE: ABBV) announced today the intent to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based…
Source: news.abbvie.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @mshadman: JNJ, AbbVie plan to pull US accelerated approvals of #ibrutinib for #MCL and #MZL https://t.co/kQFIPc5mxv
-
Ventoclax + #obinutuzumab with or without #ibrutinib was superior compared with chemoimmunotherapy as first-line treatment in patients with previously untreated, advanced #CLL. #leusm https://t.co/rRq0VRYFz7